09.05.2024 14:39:06 - dpa-AFX: *MERCK : PHASE 3 TRIAL OF KEYTRUDA PLUS CHEMOTHERAPY IN ENDOMETRIAL CANCER FAILS TO MEET MAIN GOAL

Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX
Name WKN Börse Kurs Datum/Zeit Diff. Diff. % Geld Brief Erster Schluss
Merck & Co A0YD8Q NYSE 129,670 20.06.24 22:00:07 +1,680 +1,31% 129,670 130,770 127,390 127,990

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH